EcoDrugPlus

5-Hydroxytryptamine (Serotonin) Receptor 1a B

Ensembl ID : ENSORLG00000028928
Gene Symbol: HTR1AB
1 Cross references
132 Possible Orthologues:

5-Hydroxytryptamine (Serotonin) Receptor 2a, Genome Duplicate A

Ensembl ID : ENSORLG00000013998
Gene Symbol: HTR2AA
3 Cross references
216 Possible Orthologues:

5-Hydroxytryptamine (Serotonin) Receptor 2b, G Protein-Coupled

Ensembl ID : ENSORLG00000007537
Gene Symbol: HTR2B
4 Cross references
201 Possible Orthologues:

5-Hydroxytryptamine (Serotonin) Receptor 2c, G Protein-Coupled-Like 1

Ensembl ID : ENSORLG00000008442
Gene Symbol: HTR2CL1
4 Cross references
201 Possible Orthologues:

5-Hydroxytryptamine (Serotonin) Receptor 3b

Ensembl ID : ENSORLG00000014619
Gene Symbol: HTR3B
3 Cross references
174 Possible Orthologues:

5-Hydroxytryptamine (Serotonin) Receptor 5a, Genome Duplicate B

Ensembl ID : ENSORLG00000025245
Gene Symbol: HTR5AB
4 Cross references
209 Possible Orthologues:

5-Hydroxytryptamine Receptor 1a

Ensembl ID : ENSORLG00000004220
Gene Symbol: HTR1A
2 Cross references
104 Possible Orthologues:

5-Hydroxytryptamine Receptor 1b

Ensembl ID : ENSORLG00000017292
Gene Symbol: HTR1B
2 Cross references
184 Possible Orthologues:

5-Hydroxytryptamine Receptor 1b

Ensembl ID : ENSORLG00000014940
Gene Symbol: HTR1B
2 Cross references
183 Possible Orthologues:

5-Hydroxytryptamine Receptor 3a

Ensembl ID : ENSORLG00000014631
Gene Symbol: HTR3A
4 Cross references
203 Possible Orthologues:

5-Hydroxytryptamine Receptor 4

Ensembl ID : ENSORLG00000011251
Gene Symbol: HTR4
1 Cross references
198 Possible Orthologues:

5-Hydroxytryptamine Receptor 6

Ensembl ID : ENSORLG00000023384
Gene Symbol: HTR6
4 Cross references
114 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).